Document is current
Any future updates will be listed below
-
Authors
Ito, Kae
Tsuda, Shuji
Wake, Taisei
Hatakeyama, Akira
Ogisawa, Fumiko
Ono, Mayuko
Nakayama, Riko
Wakui, Tomoko
Nagano, Nobuko
Iwata, Atsushi
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Scientific Research (25K14240)
Tokyo Metropolitan Government Support Project for Dementia Antibody Therapies
Health and Labor Sciences Research Grant (25GB0301)
- License Information
-
More Information
Article History
Received: 14 January 2026
Accepted: 26 March 2026
First Online: 30 March 2026
Declarations
:
: This study was approved by the Institutional Review Board and Ethics Committee of the Tokyo Metropolitan Institute for Geriatrics and Gerontology (approval number: R24-121) on March 13, 2025. All methods were carried out in accordance with relevant guidelines and regulations. This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to their participation in the study.
: Not applicable.
: AI has received consulting or advisory fees, research grants, and/or lecture fees from Eisai Inc.; Otsuka Pharmaceutical Co., Ltd.; Daiichi Sankyo Inc.; Kowa Co., Ltd.; FUJIREBIO Inc.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Biogen Inc.; Chugai Pharmaceutical Co., Ltd.; Sysmex Corporation; Kobayashi Pharmaceutical Co., Ltd.; Sony Group Corporation; and FUJIFILM Corporation.All other authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
